PURPOSE: This randomized controlled trial examined the quality-of-life benefits of an expressive writing (EW) intervention for patients with renal cell carcinoma (RCC) and identified a potential underlying mechanism of intervention efficacy. PATIENTS AND METHODS: Patients (N = 277) with stage I to IV RCC were randomly assigned to write about their deepest thoughts and feelings regarding their cancer (EW) or about neutral topics (neutral writing [NW]) on four separate occasions. Patients completed the Center for Epidemiologic Studies Depression Scale (CES-D), MD Anderson Symptom Inventory (MDASI), Brief Fatigue Inventory (BFI), Pittsburgh Sleep Quality Index (PSQI), Medical Outcomes Study Short Form-36 (SF-36), and Impact of Event Scale (IES) at baseline and 1, 4, and 10 months after the intervention. RESULTS:The mean age of participants (28% stage IV; 41% female) was 58 years. Multilevel modeling analyses, using a Bonferroni-corrected α = .021 for six outcomes adjusted for the correlation among outcomes, revealed that, relative to the NW group, patients in the EW group reported significantly lower MDASI scores (P = .003) and higher physical component summary scores on the SF-36 (P = .019) at 10 months after the intervention. Mediation analyses revealed that significant group differences for MDASI scores at 10 months were mediated by lower IES scores at 1 month after the intervention in the EW group (P = .042). No significant group differences were observed in the BFI, CES-D, PSQI, and mental component summary of the SF-36. CONCLUSION: EW may reduce cancer-related symptoms and improve physical functioning in patients with RCC. Evidence suggests that this effect may occur through short-term improvements in cognitive processing.
RCT Entities:
PURPOSE: This randomized controlled trial examined the quality-of-life benefits of an expressive writing (EW) intervention for patients with renal cell carcinoma (RCC) and identified a potential underlying mechanism of intervention efficacy. PATIENTS AND METHODS: Patients (N = 277) with stage I to IV RCC were randomly assigned to write about their deepest thoughts and feelings regarding their cancer (EW) or about neutral topics (neutral writing [NW]) on four separate occasions. Patients completed the Center for Epidemiologic Studies Depression Scale (CES-D), MD Anderson Symptom Inventory (MDASI), Brief Fatigue Inventory (BFI), Pittsburgh Sleep Quality Index (PSQI), Medical Outcomes Study Short Form-36 (SF-36), and Impact of Event Scale (IES) at baseline and 1, 4, and 10 months after the intervention. RESULTS: The mean age of participants (28% stage IV; 41% female) was 58 years. Multilevel modeling analyses, using a Bonferroni-corrected α = .021 for six outcomes adjusted for the correlation among outcomes, revealed that, relative to the NW group, patients in the EW group reported significantly lower MDASI scores (P = .003) and higher physical component summary scores on the SF-36 (P = .019) at 10 months after the intervention. Mediation analyses revealed that significant group differences for MDASI scores at 10 months were mediated by lower IES scores at 1 month after the intervention in the EW group (P = .042). No significant group differences were observed in the BFI, CES-D, PSQI, and mental component summary of the SF-36. CONCLUSION: EW may reduce cancer-related symptoms and improve physical functioning in patients with RCC. Evidence suggests that this effect may occur through short-term improvements in cognitive processing.
Authors: B Spivak; B Shohat; R Mester; S Avraham; I Gil-Ad; A Bleich; A Valevski; A Weizman Journal: Biol Psychiatry Date: 1997-09-01 Impact factor: 13.382
Authors: Xin Shelley Wang; Laurence D Rhines; Almon S Shiu; James N Yang; Ugur Selek; Ibrahima Gning; Ping Liu; Pamela K Allen; Syed S Azeem; Paul D Brown; Hadley J Sharp; David C Weksberg; Charles S Cleeland; Eric L Chang Journal: Lancet Oncol Date: 2012-01-27 Impact factor: 41.316
Authors: Chaan S Ng; Christopher G Wood; Paul M Silverman; Nizar M Tannir; Pheroze Tamboli; Carl M Sandler Journal: AJR Am J Roentgenol Date: 2008-10 Impact factor: 3.959
Authors: William F Pirl; Joseph A Greer; Lara Traeger; Vicki Jackson; Inga T Lennes; Emily R Gallagher; Pedro Perez-Cruz; Rebecca S Heist; Jennifer S Temel Journal: J Clin Oncol Date: 2012-03-19 Impact factor: 44.544
Authors: Susan K Lutgendorf; Donald M Lamkin; Nicholas B Jennings; Jesusa M G Arevalo; Frank Penedo; Koen DeGeest; Robert R Langley; Joseph A Lucci; Steve W Cole; David M Lubaroff; Anil K Sood Journal: Clin Cancer Res Date: 2008-11-01 Impact factor: 12.531
Authors: Isabel Leal; Kathrin Milbury; Joan Engebretson; Surena Matin; Eric Jonasch; Nizar Tannir; Christopher G Wood; Lorenzo Cohen Journal: Palliat Support Care Date: 2017-03-06
Authors: Michelle B Riba; Kristine A Donovan; Barbara Andersen; IIana Braun; William S Breitbart; Benjamin W Brewer; Luke O Buchmann; Matthew M Clark; Molly Collins; Cheyenne Corbett; Stewart Fleishman; Sofia Garcia; Donna B Greenberg; Rev George F Handzo; Laura Hoofring; Chao-Hui Huang; Robin Lally; Sara Martin; Lisa McGuffey; William Mitchell; Laura J Morrison; Megan Pailler; Oxana Palesh; Francine Parnes; Janice P Pazar; Laurel Ralston; Jaroslava Salman; Moreen M Shannon-Dudley; Alan D Valentine; Nicole R McMillian; Susan D Darlow Journal: J Natl Compr Canc Netw Date: 2019-10-01 Impact factor: 11.908
Authors: Thomas M Atkinson; Angela M Stover; Daniel F Storfer; Rebecca M Saracino; Thomas A D'Agostino; Denise Pergolizzi; Konstantina Matsoukas; Yuelin Li; Ethan Basch Journal: Epidemiol Rev Date: 2017-01-01 Impact factor: 6.222
Authors: Kathrin Milbury; Gabriel Lopez; Amy Spelman; Christopher Wood; Surena F Matin; Nizar M Tannir; Eric Jonasch; Louis Pisters; Qi Wei; Lorenzo Cohen Journal: Psychooncology Date: 2016-05-03 Impact factor: 3.894